226 related articles for article (PubMed ID: 29063830)
21. CD95 Stimulation with CD95L and DISC Analysis.
Le Gallo M; Legembre P
Methods Mol Biol; 2017; 1557():11-18. PubMed ID: 28078578
[TBL] [Abstract][Full Text] [Related]
22. CD95/Fas Increases Stemness in Cancer Cells by Inducing a STAT1-Dependent Type I Interferon Response.
Qadir AS; Ceppi P; Brockway S; Law C; Mu L; Khodarev NN; Kim J; Zhao JC; Putzbach W; Murmann AE; Chen Z; Chen W; Liu X; Salomon AR; Liu H; Weichselbaum RR; Yu J; Peter ME
Cell Rep; 2017 Mar; 18(10):2373-2386. PubMed ID: 28273453
[TBL] [Abstract][Full Text] [Related]
23. The regulation of CD95 (Fas) ligand expression in primary T cells: induction of promoter activation in CD95LP-Luc transgenic mice.
Norian LA; Latinis KM; Eliason SL; Lyson K; Yang C; Ratliff T; Koretzky GA
J Immunol; 2000 May; 164(9):4471-80. PubMed ID: 10779747
[TBL] [Abstract][Full Text] [Related]
24. CD95 is a key mediator of invasion and accelerated outgrowth of mouse colorectal liver metastases following radiofrequency ablation.
Nijkamp MW; Hoogwater FJ; Steller EJ; Westendorp BF; van der Meulen TA; Leenders MW; Borel Rinkes IH; Kranenburg O
J Hepatol; 2010 Dec; 53(6):1069-77. PubMed ID: 20832890
[TBL] [Abstract][Full Text] [Related]
25. Alleviation of off-target effects from vector-encoded shRNAs via codelivered RNA decoys.
Mockenhaupt S; Grosse S; Rupp D; Bartenschlager R; Grimm D
Proc Natl Acad Sci U S A; 2015 Jul; 112(30):E4007-16. PubMed ID: 26170322
[TBL] [Abstract][Full Text] [Related]
26. Induction of murine hepatocyte death by membrane-bound CD95 (Fas/APO-1)-ligand: characterization of an in vitro system.
Schlosser SF; Azzaroli F; Dao T; Hingorani R; Crispe IN; Boyer JL
Hepatology; 2000 Oct; 32(4 Pt 1):779-85. PubMed ID: 11003622
[TBL] [Abstract][Full Text] [Related]
27. Seed-mediated RNA interference of androgen signaling and survival networks induces cell death in prostate cancer cells.
Corbin JM; Georgescu C; Wren JD; Xu C; Asch AS; Ruiz-Echevarría MJ
Mol Ther Nucleic Acids; 2021 Jun; 24():337-351. PubMed ID: 33850637
[TBL] [Abstract][Full Text] [Related]
28. The CD95/CD95 ligand system is not the major effector in anticancer drug-mediated apoptosis.
Tolomeo M; Dusonchet L; Meli M; Grimaudo S; D'Alessandro N; Papoff G; Ruberti G; Rausa L
Cell Death Differ; 1998 Sep; 5(9):735-42. PubMed ID: 10200532
[TBL] [Abstract][Full Text] [Related]
29. NF-kappaB-independent actions of sulfasalazine dissociate the CD95L- and Apo2L/TRAIL-dependent death signaling pathways in human malignant glioma cells.
Hermisson M; Weller M
Cell Death Differ; 2003 Sep; 10(9):1078-89. PubMed ID: 12934082
[TBL] [Abstract][Full Text] [Related]
30. CD95 ligand is a proliferative and antiapoptotic signal in quiescent hepatic stellate cells.
Reinehr R; Sommerfeld A; Häussinger D
Gastroenterology; 2008 May; 134(5):1494-506. PubMed ID: 18471522
[TBL] [Abstract][Full Text] [Related]
31. Functional role of CD95 ligand in concanavalin A-induced intestinal intraepithelial lymphocyte cytotoxicity.
Ghoreschi K; Muders M; Enders GA
Immunology; 1998 Dec; 95(4):566-71. PubMed ID: 9893046
[TBL] [Abstract][Full Text] [Related]
32. Cell cycle phase-specific survival of CD95 ligand-challenged Jurkat cells: upregulation of heat-shock response.
Parr TB; Hofman FM; Kiener PA; Stohl W
Cell Immunol; 2001 Jul; 211(1):21-9. PubMed ID: 11585384
[TBL] [Abstract][Full Text] [Related]
33. Identification of the toxic 6mer seed consensus for human cancer cells.
Patel M; Bartom ET; Paudel B; Kocherginsky M; O'Shea KL; Murmann AE; Peter ME
Sci Rep; 2022 Mar; 12(1):5130. PubMed ID: 35332222
[TBL] [Abstract][Full Text] [Related]
34. Foxp3-mediated suppression of CD95L expression confers resistance to activation-induced cell death in regulatory T cells.
Weiss EM; Schmidt A; Vobis D; Garbi N; Lahl K; Mayer CT; Sparwasser T; Ludwig A; Suri-Payer E; Oberle N; Krammer PH
J Immunol; 2011 Aug; 187(4):1684-91. PubMed ID: 21746966
[TBL] [Abstract][Full Text] [Related]
35. A CD40-CD95L fusion protein interferes with CD40L-induced prosurvival signaling and allows membrane CD40L-restricted activation of CD95.
Assohou-Luty C; Gerspach J; Siegmund D; Müller N; Huard B; Tiegs G; Pfizenmaier K; Wajant H
J Mol Med (Berl); 2006 Sep; 84(9):785-97. PubMed ID: 16924474
[TBL] [Abstract][Full Text] [Related]
36. Overexpression of Dicer enhances RNAi-mediated gene silencing by short-hairpin RNAs (shRNAs) in human cells.
Mikuma T; Kawasaki H; Yamamoto Y; Taira K
Nucleic Acids Symp Ser (Oxf); 2004; (48):191-2. PubMed ID: 17150543
[TBL] [Abstract][Full Text] [Related]
37. Neutralization of the CD95 ligand by APG101 inhibits invasion of glioma cells in vitro.
Merz C; Strecker A; Sykora J; Hill O; Fricke H; Angel P; Gieffers C; Peterziel H
Anticancer Drugs; 2015 Aug; 26(7):716-27. PubMed ID: 25850884
[TBL] [Abstract][Full Text] [Related]
38. Induction of apoptosis in 9-nitrocamptothecin-treated DU145 human prostate carcinoma cells correlates with de novo synthesis of CD95 and CD95 ligand and down-regulation of c-FLIP(short).
Chatterjee D; Schmitz I; Krueger A; Yeung K; Kirchhoff S; Krammer PH; Peter ME; Wyche JH; Pantazis P
Cancer Res; 2001 Oct; 61(19):7148-54. PubMed ID: 11585748
[TBL] [Abstract][Full Text] [Related]
39. Viral IFN-regulatory factors inhibit activation-induced cell death via two positive regulatory IFN-regulatory factor 1-dependent domains in the CD95 ligand promoter.
Kirchhoff S; Sebens T; Baumann S; Krueger A; Zawatzky R; Li-Weber M; Meinl E; Neipel F; Fleckenstein B; Krammer PH
J Immunol; 2002 Feb; 168(3):1226-34. PubMed ID: 11801659
[TBL] [Abstract][Full Text] [Related]
40. Generation and Application of Bioluminescent CD95 Ligand Fusion Proteins.
Lang I; Kums J; Wajant H
Methods Mol Biol; 2017; 1557():63-77. PubMed ID: 28078583
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
